Diagnosis of Alzheimer's disease confirmed by biomarkers (imaging or biofluid evidence of amyloid-beta and tau pathology)
Mild stage of Alzheimer's disease: Clinical Dementia Rating (CDR) ≤ 1 or Quick Dementia Rating System (QDRS) ≤ 8
Medically stable and able to attend study visits and complete study procedures
On stable doses of any psychotropic medications for at least 4 weeks before the baseline visit
Not currently receiving anti-amyloid monoclonal antibody therapy
You may not be if
New or unstable neurological disorder or unstable psychiatric illness that could affect safety or study results
Clinically significant kidney or thyroid problems that pose safety concerns, or abnormal safety labs judged to be related to study drug and requiring discontinuation
Use of thiazide diuretics during the dosing period (unless stopped at least 4 weeks before baseline)
Chronic daily use of non-aspirin NSAIDs (including COX-2 inhibitors); short courses require study team approval and may require temporary study drug hold and safety labs before resuming
Starting excluded therapies during the active treatment period (e.g., anti-amyloid monoclonal antibody treatment)
Noncompliance with essential study procedures that would prevent collection of primary safety or feasibility endpoints (e.g., repeated missed visits or refusal of critical labs)
